|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.37 EUR | -0.10% |
|
+9.20% | +88.31% |
| 12-12 | Bayer Wins EU Panel's Recommendation for Eye Disease Drug's New Indication | MT |
| 12-12 | BAYER AG : Berenberg reiterates its Neutral rating | ZD |
Evolution of the Average Target: Bayer AG
Evolution of the Target Price: Bayer AG
Changes in Analyst Recommendations: Bayer AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | -6.76% | |||||
| +4.69% | |||||
| -2.48% | |||||
| +9.63% | |||||
| +2.05% | |||||
| +12.08% | |||||
| +2.06% | |||||
| +7.14% | |||||
| +22.46% | |||||
| +2.56% | |||||
| Average | +5.34% | |||||
| Weighted average by Cap. | +5.44% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BERENBERG | Sebastian Bray |
| JPMORGAN | Richard Vosser |
| BARCLAYS | Charles Pitman-King |
| DZ BANK | Peter Spengler |
| BANK OF AMERICA (BOFA) | Sachin Jain |
| JEFFERIES | Chris Counihan |
| GOLDMAN SACHS | James Quigley |
| UBS | Matthew Weston |
| BERNSTEIN RESEARCH | Florent Cespedes |
| alphavalue | Abhishek Raval |
| Baptista Research | |
| HSBC | |
| AlphaValue/Baader Europe | |
| DEUTSCHE BANK RESEARCH | Falko Friedrichs |
| STIFEL | Andreas Heine |
| Stifel Nicolaus | |
| MORGAN STANLEY | Thibault Boutherin |
| CREDIT SUISSE | Dominic Lunn |
| DEUTSCHE BANK | Falko Friedrichs |
| NORDLB | Thorsten Strauß |
| KEPLER CHEUVREUX | Christian Faitz |
| WARBURG RESEARCH | Ulrich Huwald |
| BRYAN GARNIER | Jean-Jaques Le Fur |
| INDEPENDENT RESEARCH | Tobias Gottschalt |
| BAADER BANK | Markus Mayer |
| LIBERUM CAPITAL | Graham Doyle |
| SOCIETE GENERALE (SOCGEN) | Florent Cespedes |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
- Consensus Bayer AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition